ResMed CFO Executes Stock Transaction Under Rule 10b5-1 Plan

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) just unveiled an update.

ResMed Inc. has reported a change in beneficial ownership, with Chief Financial Officer Brett Sandercock executing a transaction involving the sale of 3,644 shares of ResMed common stock at a price of $244.59 per share. This transaction was conducted under a pre-established Rule 10b5-1 plan, highlighting a strategic financial decision within the company’s management. The transaction reflects ongoing management activities and may influence stakeholder perceptions regarding the company’s financial strategies.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

ResMed Inc. operates in the healthcare industry, specializing in the development and manufacturing of products for the treatment of sleep disorders, particularly sleep apnea. The company is known for its innovative solutions and devices that aim to improve the quality of life for individuals with respiratory conditions.

Average Trading Volume: 1,368,799

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$54.91B

For an in-depth examination of RMD stock, go to TipRanks’ Stock Analysis page.